Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Roivant Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Roivant Sciences Ltd.'s regulatory disclosures and financial reporting.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme had 46,878 Common Shares withheld on June 30, 2026 at $35.39 per share. This was a tax-withholding disposition tied to the vesting of previously granted RSUs, not an open-market trade. After this net settlement, he directly holds 18,630,739 Common Shares.
Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026. She exercised options to acquire 17,750 Common Shares at an exercise price of $4.46 per share, increasing her direct common share holdings before subsequent sales.
That same day, she executed open-market sales totaling 17,750 Common Shares in two transactions: 2,748 shares at a weighted average price of $34.71 and 15,002 shares at a weighted average price of $34.32. The footnotes state these were filled across multiple trades within price ranges from $33.65 to $34.80. After the transactions, Epperly directly held 16,474 Common Shares and 169,166 stock options to purchase additional shares, with the option grant exercised here fully vested and expiring on July 19, 2032.
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share. The filing shows 200,000 shares sold from his direct holdings, leaving 1,748,403 shares held directly, and additional sales by QVT Financial Investment Cayman Ltd., which held 13,689,166 shares afterward. Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of those shares except for his pecuniary interest.
Roivant Sciences Ltd. reported insider-related share sales linked to an investment entity associated with director Daniel Allen Gold. QVT Financial Investment Cayman Ltd. completed open-market sales of a total of 1,438,163 common shares of Roivant Sciences over three days, at prices between $33.92 and $35.28 per share. After the most recent transaction, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares indirectly. Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Roivant Sciences Ltd. disclosed that investment firm QVT Financial LP, through QVT Financial Investment Cayman Ltd., executed open-market sales of a total of 1,438,163 common shares over three days at prices around $33.92–$35.28 per share. Following these transactions, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares, while footnotes state that QVT Financial LP may be deemed to beneficially own 23,723,074 Roivant common shares across related entities, although it disclaims beneficial ownership beyond any pecuniary interest.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme reported an exercise-and-sell pattern over two days. On June 25 and 26, he exercised options to acquire a total of 1,000,000 Common Shares at $3.85 per share and sold 1,000,000 Common Shares in open-market transactions.
The sales were executed at weighted average prices of $34.13 and $34.08 per share, each representing multiple trades within disclosed price ranges. Following these transactions, Sukhatme directly held 18,677,617 Common Shares. The underlying options exercised were fully vested and are no longer outstanding.
Roivant Sciences Ltd. reported insider transactions by President & Immunovant CEO Eric Venker involving both an option exercise and open-market sales of common shares.
Venker exercised stock options for 200,000 Common Shares at a conversion price of $3.85 per share and received fully vested shares. On the same date, he sold 46,234 Common Shares at a weighted average price of $33.51 and 153,766 Common Shares at a weighted average price of $33.05 in multiple open-market transactions within disclosed price ranges. Following these moves, he directly held 1,613,063 Common Shares and 4,244,834 stock options to purchase additional shares.